Clinical trial • Phase III • Other
survodutide for Healthy volunteer
Phase III trial of survodutide for Healthy volunteer. 56 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteer
- Trial Stage
- Phase III
- Drug Modality
- Peptide/protein/enzyme
Key dates
- Initial CTIS Submission Date
- 11-02-2026
- First CTIS Authorization Date
- 28-04-2026
Trial design
Phase III trial in Germany.
- Target Sample Size
- 56
Eligibility
Recruits 56 Vulnerable population not selected (isVulnerablePopulationSelected=false)..
- Vulnerable Population
- Vulnerable population not selected (isVulnerablePopulationSelected=false).
Recruitment
- Planned Sample Size
- 56
- Recruitment Window Months
- 3
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 56
Germany
- Earliest CTIS Part Ii Submission Date
- 09-04-2026
- Latest Decision Or Authorization Date
- 28-04-2026
- Processing Time Days
- 19
- Number Of Sites
- 1
- Number Of Participants
- 56
Sites
- Site Name
- CRS Clinical Research Services Management GmbH
- Contact Person Name
- Brigitte Kalsch
- Contact Person Email
- brigitte.kalsch@crs-group.de
Sponsor
Primary sponsor
- Full Name
- Boehringer Ingelheim International GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Contract research organisations
- Name
- CRS Clinical Research Services Management GmbH
- Responsibilities
- Listed as trial site / site contact (person: Brigitte Kalsch); shown as site organisation in trialSites
Investigational products
- Investigational Product Name
- survodutide
- Active Substance
- survodutide
- Modality
- Peptide/protein/enzyme
- Routes Of Administration
- pre-filled syringe or pen-like injector
Related trials
Other published trials that may interest you.